<?xml version="1.0" encoding="UTF-8"?>
<notes notes-type="funding-information">
 <title>Funding information</title>
 <p>The TLN is designed, managed, and analysed by iOMEDICO and has received continuous financial support from Celgene GmbH, Mundipharma GmbH, Onkovis GmbH, and Roche Pharma AG. None of the funding companies had any role in study design, data collection and analysis, interpretation of results, decision to publish, or preparation of the manuscript. The TLN-Group collaborates with the Arbeitskreis Klinische Studien in onkologischen und h√§matologischen Praxen e.V. (AKS) and the Kompetenznetz Maligne Lymphome (KML).</p>
</notes>
